|
1
|
Stewart LA: Chemotherapy in adult
high-grade glioma: a systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet.
359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhu VF, Yang J, Lebrun DG and Li M:
Understanding the role of cytokines in Glioblastoma Multiforme
pathogenesis. Cancer Lett. 316:139–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sathornsumetee S, Reardon DA, Desjardins
A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted
therapy for malignant glioma. Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Linz U: Commentary on effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet
Oncol 2009;10:459–466). Cancer. 116:1844–1846. 2010.PubMed/NCBI
|
|
5
|
Pulkkanen KJ and Yla-Herttuala S: Gene
therapy for malignant glioma: current clinical status. Mol Ther.
12:585–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dorn GW 2nd and Mochly-Rosen D:
Intracellular transport mechanisms of signal transducers. Annu Rev
Physiol. 64:407–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adams DR, Ron D and Kiely PA: RACK1, a
multifaceted scaffolding protein: structure and function. Cell
Commun Signal. 9:222011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wan L, Xie Y, Su L, Liu Y, Wang Y and Wang
Z: RACK1 affects morphine reward via BDNF. Brain Res. 1416:26–34.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Battaini F, Pascale A, Paoletti R and
Govoni S: The role of anchoring protein RACK1 in PKC activation in
the ageing rat brain. Trends Neurosci. 20:410–415. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marqués N, Sesé M, Cánovas V, et al:
Regulation of protein translation and c-Jun expression by prostate
tumor overexpressed 1. Oncogene. Mar 04–2013.(Epub ahead of print).
View Article : Google Scholar
|
|
11
|
Guo Y, Wang W, Wang J, et al: Receptor for
activated C kinase 1 promotes hepatocellular carcinoma growth by
enhancing mitogen-activated protein kinase kinase 7 activity.
Hepatology. 57:140–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao XX, Xu JD, Xu JW, et al: RACK1
promotes breast carcinoma migration/metastasis via activation of
the RhoA/Rho kinase pathway. Breast Cancer Res Treat. 126:555–563.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trerotola M, Li J, Alberti S and Languino
LR: Trop-2 inhibits prostate cancer cell adhesion to fibronectin
through the β1 integrin-RACK1 axis. J Cell Physiol. 227:3670–3677.
2012.PubMed/NCBI
|
|
14
|
Wu J, Meng J, Du Y, et al: RACK1 promotes
the proliferation, migration and invasion capacity of mouse
hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1
signaling pathway. Biomed Pharmacother. 67:313–319. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruan Y, Sun L, Hao Y, et al: Ribosomal
RACK1 promotes chemoresistance and growth in human hepatocellular
carcinoma. J Clin Invest. 122:2554–2566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li G, Ji XD, Gao H, et al: EphB3
suppresses non-small-cell lung cancer metastasis via a
PP2A/RACK1/Akt signalling complex. Nat Commun. 3:6672012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu F, Zhang C, Wu WJ and Wu YM: RACK1
downregulation suppresses migration and proliferation of
neuroblastoma cell lines. Oncol Rep. 27:1646–1652. 2012.PubMed/NCBI
|
|
18
|
Li J, Guo Y, Feng X, et al: Receptor for
activated C kinase 1 (RACK1): a regulator for migration and
invasion in oral squamous cell carcinoma cells. J Cancer Res Clin
Oncol. 138:563–571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Osawa T, Tsuchida R, Yuasa Y and
Shibuya M: Downregulation of receptor for activated C-kinase 1
(RACK1) suppresses tumor growth by inhibiting tumor cell
proliferation and tumor-associated angiogenesis. Cancer Sci.
102:2007–2013. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Delft MF, Wei AH, Mason KD, et al: The
BH3 mimetic ABT-737 targets selective Bcl-2 proteins and
efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell. 10:389–399. 2006.PubMed/NCBI
|
|
21
|
Gelman IH: Src-family tyrosine kinases as
therapeutic targets in advanced cancer. Front Biosci. 3:801–807.
2011.PubMed/NCBI
|
|
22
|
Aleshin A and Finn RS: SRC: a century of
science brought to the clinic. Neoplasia. 12:599–607.
2010.PubMed/NCBI
|
|
23
|
Doan AT and Huttenlocher A: RACK1
regulates Src activity and modulates paxillin dynamics during cell
migration. Exp Cell Res. 313:2667–2679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huveldt D, Lewis-Tuffin LJ, Carlson BL, et
al: Targeting Src family kinases inhibits bevacizumab-induced
glioma cell invasion. PLoS One. 8:e565052013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stedt H, Alasaarela L, Samaranayake H, et
al: Specific inhibition of SRC kinase impairs malignant glioma
growth in vitro and in vivo. Mol Ther Nucleic Acids. 1:e192012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Creedon H and Brunton VG: Src kinase
inhibitors: promising cancer therapeutics? Crit Rev Oncog.
17:145–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheppard K, Kinross KM, Solomon B, Pearson
RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in
cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hemmings BA and Restuccia DF: PI3K-PKB/Akt
pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mamidipudi V and Cartwright CA: A novel
pro-apoptotic function of RACK1: suppression of Src activity in the
intrinsic and Akt pathways. Oncogene. 28:4421–4433. 2009.
View Article : Google Scholar : PubMed/NCBI
|
